Addex Therapeutics (NASDAQ:ADXN) Trading 2% Higher – Here’s Why

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN)’s stock price traded up 2% during trading on Monday . The stock traded as high as $7.46 and last traded at $7.3560. 11,289 shares changed hands during trading, an increase of 213% from the average session volume of 3,611 shares. The stock had previously closed at $7.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Addex Therapeutics presently has a consensus rating of “Sell”.

Addex Therapeutics Price Performance

The stock has a 50-day moving average price of $7.85 and a 200-day moving average price of $8.36. The firm has a market capitalization of $9.05 million, a PE ratio of -1.28 and a beta of 1.46.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.